SCHEDULE AN APPOINTMENT (717) 541-9700

One of the foremost eye surgeons in the nation.


silbert_sxPEDIATRIC SURGERY SPECIALITIES

  • Strabismus surgery (lazy eye and/or double vision)

  • Nasolacrimal duct surgery (for watery eyes)

  • Ptosis surgery (droopy eyelid)

  • Chalazion and eyelid lesions

  • Orbital fracture repair

  • Capillary Hemangioma

  • Enucleation

  • Surgery for abnormal head posture cause by strabismus or nystagmus


ADULT SURGERY SPECIALITIES

  • Eyelid and Laser Surgery

  • Upper Eyelid Lift

  • Brow Lift

  • Lower Eyelid Lift

  • Cortex Fraction C02 and Erbium Laser Facial Resurfacing

  • Ectropion (outward turning eyelid)

  • Entropion (in-turning eyelid)

  • Skin cancer removal and reconstructive eyelid surgery

  • Dacryocystorhinostomy (DCR) for tearing


Non-Surgical/In-Office Cosmetic Treatment

Botox is the most popular non-surgical cosmetic treatment in America. It is a highly purified, naturally occurring protein, which has the ability to very precisely relax the muscles to which it is applied. This reduces severe lines between the eyes and forehead, crow’s feet and bunny lines. Special attention is given to honor each patient’s natural expression and features.

Juvederm Dermal Filler – Young, healthy-looking skin contains an abundance of a naturally hydrating substance called hyaluronic acid (HA). But as you age, sunlight and other factors can reduce the amount of HA in your skin. The lack of HA causes skin to lose structure and volume, creating unwanted facial wrinkles and folds – like parentheses lines around the nose and mouth. Having a filler treatment is a safe and effective to replace the HA that your skin has lost, bringing back volume and smoothing away facial depressions and folds.

Blemish Removal – A number of minor blemishes like moles, warts, and skin tags may affect your appearance. Many clients seek removal for cosmetic reasons. Removal of skin lesions requires only about 30 minutes and can be performed under a local anesthetic.

By the numbers


21 YEARS IN PRACTICE
MORE THAN 10,000 SURGICAL PROCEDURES
MORE THAN 50 RESEARCH PAPERS AND PROPOSALS SUMITTED
OVER 150,000 PATIENTS SEEN

Completed Studies


Pediatric

Pediatric Eye Disease Investigator Group C02 Pediatric cataract surgery registry

Pediatric Eye Disease Investigator Group CITS Convergence insufficiency treatment study

Pediatric Eye Disease Investigator Group IXT1 Randomized trial of bilateral lateral rectus recession versus unilateral recess-resect for intermittent exotropia

Pediatric Eye Disease Investigator Group IXT2 Randomized clinical trial of observation versus occlusion therapy for intermittent exotropia

Pediatric Eye Disease Investigator Group IXT3 A pilot randomization clinical trial of overminus therapy for intermittent exotropia

Pediatric Eye Disease Investigator Group E02 Esotropia treatment with Botox data collection

GoCheck Prospective Evaluation of mobile phone photography application as a vision screening tool in children

Pediatric Eye Disease Investigator Group ATS18 Study of binocular computer activities for treatment of amblyopia

Pediatric Eye Disease Investigator Group protocol HTS1 Glasses vs observation for moderate hyperopia in young children

Pediatric Eye Disease Investigator Group protocol ATS17 A Randomized trial of Levodopa as treatment for residual amblyopia

Pediatric Eye Disease Investigator Group protocol CITS Convergence insufficiency treatment study

Pediatric Eye Disease Investigator Group protocol HTS1 Glasses vs observation for moderate hyperopia in young children

Pediatric Eye Disease Investigator Group protocol A16 Augmenting Atropine Treatment for Amblyopia

Pediatric Eye Disease Investigator Group protocol A15 – Increasing Patching for Amblyopia

Pediatric Eye Disease Investigator Group protocol A14 A pilot study to evaluate Levodopa as treatment for residual amblyopia in 8 to 17 year olds

Pediatric Eye Disease Investigator Group protocol A13 An observational study of optical correction for strabismic amblyopia in children 3 to <7 years old

Pediatric Eye Disease Investigator Group protocol A12 A Randomized Trial Comparing Patching with Active Vision Therapy to Patching with Control Vision Therapy for Amblyopia in Children 7 to < 13 Years Old

Pediatric Eye Disease Investigator Group protocol A11 A Randomized Trial to Evaluate 8 Hours of Daily Patching Plus Daily Atropine for Residual Amblyopia in Children 3 to <8 Years Old

Pediatric Eye Disease Investigator Group protocol A10 A Randomized Trial of Full-time Bangerter Filters versus Part-time Daily Patching for the Treatment of Moderate Amblyopia in Children

Pediatric Eye Disease Investigator Group protocol ATS9 A Randomized Trial Comparing Patching Versus Atropine for Amblyopia in 7 to <13 Year Olds

Pediatric Eye Disease Investigator Group protocol ATS8 A Randomized Trial Comparing Atropine to Atropine Plus a Reduced-Plus Lens for the Sound Eye as Treatments for Amblyopia in Children 3 to <7

Pediatric Eye Disease Investigator Group protocol ATS7 Bilateral Refractive Amblyopia Treatment Study

Pediatric Eye Disease Investigator Group protocol ATS6 A Randomized Trial to Compare Near Versus Distance Activities While Patching for Amblyopia

Pediatric Eye Disease Investigator Group protocol ATS5 Treatment of Anisometropic Amblyopia in Children with Refractive Correction

Pediatric Eye Disease Investigator Group protocol ATS4 A Randomized Trial of Atropine Regimens for Treatment of Moderate Amblyopia in Children

Pediatric Eye Disease Investigator Group protocol ATS3 A prospective, pilot study of treatment of amblyopia in children 10 to <18 years old

Pediatric Eye Disease Investigator Group protocol ATS2A A randomized trial comparing part-time vs. full-time patching for severe amblyopia

Pediatric Eye Disease Investigator Group protocol ATS2B A randomized trial comparing part-time versus minimal-time patching for moderate amblyopia

Pediatric Eye Disease Investigator Group protocol ATS2C Risk of amblyopia recurrence after cessation of treatment

Pediatric Eye Disease Investigator Group protocol ATS1 A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children

Pediatric Eye Disease Investigator Group protocol NLD 1 A Prospective Study of Primary Surgical Treatment of Nasolacrimal Duct Obstruction in Children Less Than Four Years Old

Pediatric Eye Disease Investigator Group protocol NLD2 A Prospective Study of Surgical Procedures for the Treatment of Persistent Nasolacrimal Duct Obstruction in Children < 4 years old

Pediatric Eye Disease Investigator Group protocol NLD3 A Randomized Trial Comparing Immediate Probing in an Office Setting with Deferred Probing in a Facility Setting for Treatment of Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old

Pediatric Eye Disease Investigator Group protocol ETS1 An Observational Study of Infantile, Acquired Non-accommodative, and Acquired Partially-accommodative Esotropia

Pediatric Eye Disease Investigator Group protocol CCT A Prospective Study of Central Corneal Thickness in Children Less than 18 Years old

Pediatric Eye Disease Investigator Group protocol COMET2 A randomized trial of the effect of progressive addition lenses versus single vision lenses on low myopia associated with large accommodative lags and near esophoria in children

Pediatric Eye Disease Investigator Group protocol X01 Correction of Refractive Error for Amblyopia Study

Bausch & Lomb A randomized, double-masked, active-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of topical besifloxacin ophthalmic suspension, 0.6% compared with gatifloxacin, 0.3% ophthalmic solution for the treatment of presumed bacterial conjunctivitis in subjects from birth to 31 days of age

Bausch & Lomb A Clinical and Efficacy Evaluation of Zylet (Ioteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) compared to Lotemax (Ioteprednol etabonate ophthalmic suspension 0.5%), Tobramycin Ophthalmic Solution USP, 0.3%, and the Vehicle of Zylet for the Treatment of Blepharoconjunctivitis in Pediatric Subjects

Bausch & Lomb Study #459 A Safety and Efficacy Study of Zylet® (Ioteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) Compared to Vehicle in the Management of Lid Inflammation in Pediatric Subjects

Dry Eye

Alcon Evaluation of ESBa105 in the persistent relief of ocular discomfort in patients with severe dry eye

Inspire A multi-center, parallel-group, double-masked, randomized, placebo-controlled study of the effects of diquafosol tetrasodium ophthalmic solution, 2% in subjects with dry eye disease and a central corneal staining score of 3 (NEI Scale)

Alcon A Randomize, Double-Masked and Efficacy Study of FID #109980 Compared to FID #110656 in the Treatment of Dry Eye

Lexitas Dry Eye Study A multi-center, double-masked, randomized, controlled, efficacy and safety study of EBI-005 5 mg/mL topical ophthalmic solution versus vehicle control in subjets with moderate to severe dry eye disease

TearScience LF-001 Randomized Clinical Trial for Treatment of Meibomian Gland Dysfunction and Evaporation Dry Eye

Conjunctivitis

Bausch & Lomb A study to evaluate the clinical and microbial efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID compared to vehicle in the treatment of bacterial conjunctivitis

Bausch & Lomb Study A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis

Optic Neuropathy

Eli Lilly Study of the possible association between the use of PDE5 inhibitors and the risk of acute nonarteritic anterior ischemic optic neuropathy (NAION)

Pfizer study A1481259 Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential “Trigger Factor” for Acute NAION

Cataract Surgery

Bausch & Lomb A randomized, multicenter, double-masked, parallel-group, clinical safety and efficacy evaluation of loteprednol etabonate ophthalmic gel, 0.5% versus vehicle for the treatment of inflammation and pain following cataract surgery

Bausch & Lomb A phase 3, multi-center, double-masked, vehicle-controlled, randomized, parallel-group study to assess loteprednol etabonate ophthalmic gel, 0.38% versus vehicle gel for the treatment of ocular inflammation and pain following cataract surgery

Other

Inspire Study Phase IV. A Multi-Center, Open-Label, Registry of Epinastine HCl Ophthalmic Solution, 0.05% (Elestat) in Subjects with History and Current Complaint of Ocular Allergy Symptom

A clinical evaluation of Juvederm Ultra Injectable Gel for the correction of moderate to severe facial wrinkles and folds ( Silbert)

Study utilizing the platelet factor 4 – fluorescein method for examination of endothelial cell surface and platelet surface proteoglycans

Study Developing a platelet factor 4 – fluorescein probe and applied it to the examination of the content and distribution of cell surface proteoglycans in cultures of several types of cells

Study on organic synthesis of histochemical dyes

Specialities and Research

Updated on 2016-11-16T20:47:02+00:00, by admin.